BACKGROUND: Despite advances in treatments for Hodgkin's lymphoma, about 20% of patients still die from progressive disease. Current prognostic models predict the outcome of treatment with imperfect accuracy, and clinically relevant biomarkers have not been established to improve on the International Prognostic Score. METHODS: Using gene-expression profiling, we analyzed 130 frozen samples obtained from patients with classic Hodgkin's lymphoma during diagnostic lymph-node biopsy to determine which cellular signatures were correlated with treatment outcome. We confirmed our findings in an independent cohort of 166 patients, using immunohistochemical analysis. RESULTS: Gene-expression profiling identified a gene signature of tumor-associated macrophages that was significantly associated with primary treatment failure (P=0.02). In an independent cohort of patients, we found that an increased number of CD68+ macrophages was correlated with a shortened progression-free survival (P=0.03) and with an increased likelihood of relapse after autologous hematopoietic stem-cell transplantation (P=0.008), resulting in shortened disease-specific survival (P=0.003). In multivariate analysis, this adverse prognostic factor outperformed the International Prognostic Score for disease-specific survival (P=0.003 vs. P=0.03). The absence of an elevated number of CD68+ cells in patients with limited-stage disease defined a subgroup of patients with a long-term disease-specific survival of 100% with the use of current treatment strategies. CONCLUSIONS: An increased number of tumor-associated macrophages was strongly associated with shortened survival in patients with classic Hodgkin's lymphoma and provides a new biomarker for risk stratification. 2010 Massachusetts Medical Society
BACKGROUND: Despite advances in treatments for Hodgkin's lymphoma, about 20% of patients still die from progressive disease. Current prognostic models predict the outcome of treatment with imperfect accuracy, and clinically relevant biomarkers have not been established to improve on the International Prognostic Score. METHODS: Using gene-expression profiling, we analyzed 130 frozen samples obtained from patients with classic Hodgkin's lymphoma during diagnostic lymph-node biopsy to determine which cellular signatures were correlated with treatment outcome. We confirmed our findings in an independent cohort of 166 patients, using immunohistochemical analysis. RESULTS: Gene-expression profiling identified a gene signature of tumor-associated macrophages that was significantly associated with primary treatment failure (P=0.02). In an independent cohort of patients, we found that an increased number of CD68+ macrophages was correlated with a shortened progression-free survival (P=0.03) and with an increased likelihood of relapse after autologous hematopoietic stem-cell transplantation (P=0.008), resulting in shortened disease-specific survival (P=0.003). In multivariate analysis, this adverse prognostic factor outperformed the International Prognostic Score for disease-specific survival (P=0.003 vs. P=0.03). The absence of an elevated number of CD68+ cells in patients with limited-stage disease defined a subgroup of patients with a long-term disease-specific survival of 100% with the use of current treatment strategies. CONCLUSIONS: An increased number of tumor-associated macrophages was strongly associated with shortened survival in patients with classic Hodgkin's lymphoma and provides a new biomarker for risk stratification. 2010 Massachusetts Medical Society
Authors: Arthur L Shaffer; George Wright; Liming Yang; John Powell; Vu Ngo; Laurence Lamy; Lloyd T Lam; R Eric Davis; Louis M Staudt Journal: Immunol Rev Date: 2006-04 Impact factor: 12.988
Authors: J B Perz; C Giles; R Szydlo; D O'Shea; J Sanz; A Chaidos; S Wagner; J Davis; S Loaiza; D Marin; J Apperley; E Olavarria; A Rahemtulla; I Lampert; K Naresh; D Samson; D MacDonald; E J Kanfer Journal: Bone Marrow Transplant Date: 2006-11-20 Impact factor: 5.483
Authors: Sandeep S Dave; Kai Fu; George W Wright; Lloyd T Lam; Philip Kluin; Evert-Jan Boerma; Timothy C Greiner; Dennis D Weisenburger; Andreas Rosenwald; German Ott; Hans-Konrad Müller-Hermelink; Randy D Gascoyne; Jan Delabie; Lisa M Rimsza; Rita M Braziel; Thomas M Grogan; Elias Campo; Elaine S Jaffe; Bhavana J Dave; Warren Sanger; Martin Bast; Julie M Vose; James O Armitage; Joseph M Connors; Erlend B Smeland; Stein Kvaloy; Harald Holte; Richard I Fisher; Thomas P Miller; Emilio Montserrat; Wyndham H Wilson; Manisha Bahl; Hong Zhao; Liming Yang; John Powell; Richard Simon; Wing C Chan; Louis M Staudt Journal: N Engl J Med Date: 2006-06-08 Impact factor: 91.245
Authors: Michael D Duff; Juan Mestre; Sirish Maddali; Zhao Ping Yan; Philip Stapleton; John M Daly Journal: J Surg Res Date: 2007-06-27 Impact factor: 2.192
Authors: Arjan Diepstra; Gustaaf W van Imhoff; Henrike E Karim-Kos; Anke van den Berg; Gerard J te Meerman; Marijke Niens; Ilja M Nolte; Esther Bastiaannet; Michael Schaapveld; Edo Vellenga; Sibrand Poppema Journal: J Clin Oncol Date: 2007-05-29 Impact factor: 44.544
Authors: Abel Sánchez-Aguilera; Carlos Montalbán; Paloma de la Cueva; Lydia Sánchez-Verde; Manuel M Morente; Mónica García-Cosío; José García-Laraña; Carmen Bellas; Mariano Provencio; Vicens Romagosa; Alberto Fernández de Sevilla; Javier Menárguez; Pilar Sabín; María J Mestre; Miguel Méndez; Manuel F Fresno; Concepción Nicolás; Miguel A Piris; Juan F García Journal: Blood Date: 2006-03-21 Impact factor: 22.113
Authors: Todd A Fehniger; Sarah Larson; Kathryn Trinkaus; Marilyn J Siegel; Amanda F Cashen; Kristie A Blum; Timothy S Fenske; David D Hurd; Andre Goy; Stephanie E Schneider; Catherine R Keppel; Nina D Wagner-Johnston; Kenneth R Carson; Nancy L Bartlett Journal: Blood Date: 2011-09-21 Impact factor: 22.113
Authors: Beatriz Sánchez-Espiridión; Ana M Martin-Moreno; Carlos Montalbán; L Jeffrey Medeiros; Francisco Vega; Anas Younes; Miguel A Piris; Juan F Garcia Journal: Haematologica Date: 2012-02-07 Impact factor: 9.941